Addex Therapeutics (ADXN) Competitors $10.70 +0.95 (+9.74%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ADXN vs. QNCX, TARA, PRPH, IMMX, VTVT, DRRX, CALC, RLYB, ATRA, and ORGSShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Quince Therapeutics (QNCX), Protara Therapeutics (TARA), ProPhase Labs (PRPH), Immix Biopharma (IMMX), vTv Therapeutics (VTVT), DURECT (DRRX), CalciMedica (CALC), Rallybio (RLYB), Atara Biotherapeutics (ATRA), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Quince Therapeutics Protara Therapeutics ProPhase Labs Immix Biopharma vTv Therapeutics DURECT CalciMedica Rallybio Atara Biotherapeutics Orgenesis Addex Therapeutics (NASDAQ:ADXN) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations. Is ADXN or QNCX more profitable? Addex Therapeutics has a net margin of 463.11% compared to Quince Therapeutics' net margin of 0.00%. Quince Therapeutics' return on equity of -46.04% beat Addex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Addex Therapeutics463.11% -190.29% -111.20% Quince Therapeutics N/A -46.04%-24.34% Do analysts rate ADXN or QNCX? Addex Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 180.37%. Quince Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 614.29%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 Which has more volatility & risk, ADXN or QNCX? Addex Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Does the media favor ADXN or QNCX? In the previous week, Quince Therapeutics had 8 more articles in the media than Addex Therapeutics. MarketBeat recorded 8 mentions for Quince Therapeutics and 0 mentions for Addex Therapeutics. Quince Therapeutics' average media sentiment score of 0.40 beat Addex Therapeutics' score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Addex Therapeutics Neutral Quince Therapeutics Neutral Do insiders & institutionals believe in ADXN or QNCX? 16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 16.8% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in ADXN or QNCX? Addex Therapeutics received 12 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 51.72% of users gave Addex Therapeutics an outperform vote. CompanyUnderperformOutperformAddex TherapeuticsOutperform Votes1551.72% Underperform Votes1448.28% Quince TherapeuticsOutperform Votes3100.00% Underperform VotesNo Votes Which has better valuation and earnings, ADXN or QNCX? Addex Therapeutics has higher revenue and earnings than Quince Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAddex Therapeutics$829.94K13.67-$11.76M-$1.64-6.52Quince TherapeuticsN/AN/A-$31.39M-$1.26-1.22 SummaryQuince Therapeutics beats Addex Therapeutics on 12 of the 17 factors compared between the two stocks. Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.34M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.15%4.14%P/E Ratio-6.529.36112.5515.07Price / Sales13.67386.151,478.8293.55Price / CashN/A47.3339.8334.04Price / Book8.925.324.645.01Net Income-$11.76M$153.56M$119.13M$225.46M7 Day Performance-2.82%0.12%0.78%0.37%1 Month Performance15.30%15.23%5.65%3.57%1 Year Performance76.86%41.16%36.90%29.42% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics1.5096 of 5 stars$10.70+9.7%$30.00+180.4%+62.1%$11.34M$829,941.00-6.5230Gap UpQNCXQuince Therapeutics3.2218 of 5 stars$1.08-9.2%N/A+59.4%$46.67MN/A-0.8660Analyst ForecastNews CoverageHigh Trading VolumeTARAProtara Therapeutics2.1529 of 5 stars$2.26+13.0%$24.00+961.9%+105.8%$46.53MN/A-0.7130High Trading VolumePRPHProPhase Labs3.0977 of 5 stars$2.39+3.5%$11.00+360.3%-51.9%$45.60M$44.38M-1.98130News CoveragePositive NewsGap UpIMMXImmix Biopharma3.3167 of 5 stars$1.66+4.4%$7.00+321.7%-52.1%$45.57MN/A-1.989Positive NewsVTVTvTv TherapeuticsN/A$14.81-0.4%N/A-14.5%$44.58M$1M-2.169Gap UpDRRXDURECT2.7703 of 5 stars$1.43-1.4%$21.00+1,368.5%-55.0%$44.39M$8.41M-2.3480CALCCalciMedica3.4565 of 5 stars$4.03-2.7%$20.67+413.5%+63.3%$43.27MN/A-2.8730Insider BuyingShort Interest ↓News CoverageRLYBRallybio3.1452 of 5 stars$1.03+4.0%$10.00+870.9%-76.1%$42.69M$299,000.00-0.5840Analyst ForecastATRAAtara Biotherapeutics3.3919 of 5 stars$8.60+1.7%$14.00+62.8%-69.2%$41.43M$62.39M-0.22165Upcoming EarningsGap UpORGSOrgenesis1.8506 of 5 stars$1.20+0.8%N/AN/A$41.34M$662,000.000.00150Positive NewsGap Up Related Companies and Tools Related Companies Quince Therapeutics Alternatives Protara Therapeutics Alternatives ProPhase Labs Alternatives Immix Biopharma Alternatives vTv Therapeutics Alternatives DURECT Alternatives CalciMedica Alternatives Rallybio Alternatives Atara Biotherapeutics Alternatives Orgenesis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADXN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
